Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453

Phase 1 Completed 80 enrolled Bial - Portela C S.A.

RandomizedParallel-groupDouble-blindTreatment

The purpose of this study is to assess the safety and tolerability of BIA 5-453 after single oral doses

Evaluation	Drug	Modality	Dose	Route
Subject	BIA 5-453	Unknown	2 mg	Oral
Subject	BIA 5-453	Unknown	10 mg	Oral
Subject	BIA 5-453	Unknown	20 mg	Oral
Subject	BIA 5-453	Unknown	50 mg	Oral
Subject	BIA 5-453	Unknown	100 mg	Oral
Subject	BIA 5-453	Unknown	200 mg	Oral
Subject	BIA 5-453	Unknown	400 mg	Oral
Subject	BIA 5-453	Unknown	600 mg	Oral
Subject	BIA 5-453	Unknown	900 mg	Oral
Subject	BIA 5-453	Unknown	1200 mg	Oral